

Kihyun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1234639/publications.pdf>

Version: 2024-02-01

175
papers

6,537
citations

70961

41
h-index

79541

73
g-index

177
all docs

177
docs citations

177
times ranked

7994
citing authors

#	ARTICLE	IF	CITATIONS
1	An Ultrasensitive Silicon-Based Electrolyte-Gated Transistor for the Detection of Peanut Allergens. <i>Biosensors</i> , 2022, 12, 24.	2.3	4
2	Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2022, 42, 558-565.	1.2	5
3	Influence of Radiation-Induced Displacement Defect in 1.2 kV SiC Metal-Oxide-Semiconductor Field-Effect Transistors. <i>Micromachines</i> , 2022, 13, 901.	1.4	2
4	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , 2021, 35, 1797-1802.	3.3	14
5	Recent advances in sensitive surface-enhanced Raman scattering-based lateral flow assay platforms for point-of-care diagnostics of infectious diseases. <i>Sensors and Actuators B: Chemical</i> , 2021, 329, 129214.	4.0	65
6	Insights into radiation displacement defect in an insulated-gate bipolar transistor. <i>AIP Advances</i> , 2021, 11, .	0.6	5
7	Surface-Enhanced Raman Scattering-Based Dual-Flow Lateral Flow Assay Sensor for the Ultrasensitive Detection of the Thyroid-Stimulating Hormone. <i>Analytical Chemistry</i> , 2021, 93, 6673-6681.	3.2	29
8	A Pipelined Noise-Shaping SAR ADC Using Ring Amplifier. <i>Electronics (Switzerland)</i> , 2021, 10, 1968.	1.8	2
9	SERS-based serodiagnosis of acute febrile diseases using plasmonic nanopopcorn microarray platforms. <i>Biosensors and Bioelectronics</i> , 2021, 192, 113525.	5.3	14
10	Conception and Simulation of a 2-Then-1-Bit/Cycle Noise-Shaping SAR ADC. <i>Electronics (Switzerland)</i> , 2021, 10, 2545.	1.8	2
11	Lumped-Capacitive Modeling and Sensing Characteristics of an Electrolyte-Gated FET Biosensor for the Detection of the Peanut Allergen. <i>IEEE Access</i> , 2021, 9, 168922-168929.	2.6	1
12	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , 2020, 40, 88-91.	1.2	1
13	Nanosensor-Based Real-Time Monitoring of Stress Biomarkers in Human Saliva Using a Portable Measurement System. <i>ACS Sensors</i> , 2020, 5, 4081-4091.	4.0	26
14	Solar Cell Using Hourglass-Shaped Silicon Nanowires for Increased Light-Trapping Path. <i>IEEE Journal of Photovoltaics</i> , 2020, 10, 475-479.	1.5	13
15	Buffer solution optimization for accurate fluoride ion detection in tap water. <i>Journal of Electroanalytical Chemistry</i> , 2020, 858, 113837.	1.9	10
16	Intrinsic plasticity of silicon nanowire neurotransistors for dynamic memory and learning functions. <i>Nature Electronics</i> , 2020, 3, 398-408.	13.1	37
17	Corrections to "Solar Cell Using Hourglass-Shaped Silicon Nanowires for Increased Light-Trapping Path" [Mar 20 475-479]. <i>IEEE Journal of Photovoltaics</i> , 2020, 10, 1508-1508.	1.5	0
18	Weakly Tapered Silicon Nanopillar Resonators with Spatially Well-Separated Whispering Gallery Modes for Si-Based Lasers. <i>ACS Applied Nano Materials</i> , 2019, 2, 4852-4858.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Quantitative Serodiagnosis of Scrub Typhus Using Surface-Enhanced Raman Scattering-Based Lateral Flow Assay Platforms. <i>Analytical Chemistry</i> , 2019, 91, 12275-12282.	3.2	67
20	SERS-Based Immunoassays for the Detection of Botulinum Toxins A and B Using Magnetic Beads. <i>Sensors</i> , 2019, 19, 4081.	2.1	21
21	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)â€™a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , 2019, 9, 83.	2.8	9
22	Whispering gallery modes enhance the near-infrared photoresponse of hourglass-shaped silicon nanowire photodiodes. <i>Nature Electronics</i> , 2019, 2, 572-579.	13.1	28
23	Sensitivity Analysis of Silicon Nanowire ISFET Sensor with LaF3 membrane. , 2019, , .		0
24	Interface Engineering to Enhance the Photoresponse of Core-Shell Structure Silicon Nanowire Photodetectors. , 2019, , .		1
25	Thermal Conductivity of Rough Silicon Nanowires with Silicide Layer. , 2019, , .		1
26	Design Guidelines for High Sensitivity ZnO Nanowire Gas Sensors With Schottky Contact. <i>IEEE Sensors Journal</i> , 2019, 19, 976-981.	2.4	10
27	Vertical Silicon Nanowire Thermoelectric Modules with Enhanced Thermoelectric Properties. <i>Nano Letters</i> , 2019, 19, 747-755.	4.5	40
28	LaF3 electrolyte-insulator-semiconductor sensor for detecting fluoride ions. <i>Sensors and Actuators B: Chemical</i> , 2019, 279, 183-188.	4.0	28
29	Bandgap Engineering and Strain Effects of Coreâ€™Shell Tunneling Field-Effect Transistors. <i>IEEE Transactions on Electron Devices</i> , 2018, 65, 277-281.	1.6	11
30	Ultrasensitive detection of Ebola matrix protein in a memristor mode. <i>Nano Research</i> , 2018, 11, 1057-1068.	5.8	43
31	Highly sensitive detection of high-risk bacterial pathogens using SERS-based lateral flow assay strips. <i>Sensors and Actuators B: Chemical</i> , 2018, 270, 72-79.	4.0	124
32	Performance and Variations Induced by Single Interface Trap of Nanowire FETs at 7-nm Node. <i>IEEE Transactions on Electron Devices</i> , 2017, 64, 339-345.	1.6	24
33	Optimization of Signal to Noise Ratio in Silicon Nanowire ISFET Sensors. <i>IEEE Sensors Journal</i> , 2017, 17, 2792-2796.	2.4	13
34	Core-shell homojunction silicon vertical nanowire tunneling field-effect transistors. <i>Scientific Reports</i> , 2017, 7, 41142.	1.6	17
35	Optical Characteristics of Silicon-Based Asymmetric Vertical Nanowire Photodetectors. <i>IEEE Transactions on Electron Devices</i> , 2017, 64, 2261-2266.	1.6	12
36	Negative Photoconductance in Heavily Doped Si Nanowire Field-Effect Transistors. <i>Nano Letters</i> , 2017, 17, 6727-6734.	4.5	69

#	ARTICLE	IF	CITATIONS
37	Gap engineering for improved control of memristor nanosensors. , 2017, , .		0
38	Silicon nanowire based thermoelectric device for energy harvesting. , 2017, , .		0
39	Polysilicon near-infrared photodetector with performance comparable to crystalline silicon devices. Optics Express, 2017, 25, 32910.	1.7	5
40	Variability study of Si nanowire FETs with different junction gradients. AIP Advances, 2016, 6, 015318.	0.6	10
41	Silicon-Based BioFETs with 3-D Nanostructure: Easy integration, precise control of nanostructure, and a low device-to-device variation. IEEE Nanotechnology Magazine, 2016, 10, 21-29.	0.9	0
42	Silicon nanowire biosensors for detection of cardiac troponin I (cTnI) with high sensitivity. Biosensors and Bioelectronics, 2016, 77, 695-701.	5.3	167
43	High efficiency silicon solar cell based on asymmetric nanowire. Scientific Reports, 2015, 5, 11646.	1.6	54
44	Noise consideration for cancer marker detection using nanowire. , 2014, , .		0
45	Electrical and pH sensing characteristics of Si nanowire-based suspended FET biosensors. , 2014, , .		6
46	Central nervous system multiple myeloma: a different cytogenetic profile?. British Journal of Haematology, 2014, 164, 745-748.	1.2	7
47	Clinical profiles of multiple myeloma in Asiaâ€”An Asian Myeloma Network study. American Journal of Hematology, 2014, 89, 751-756.	2.0	88
48	Suspended honeycomb nanowire ISFETs for improved stiction-free performance. Nanotechnology, 2014, 25, 345501.	1.3	20
49	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. Acta Haematologica, 2014, 131, 193-199.	0.7	23
50	Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts. Annals of Hematology, 2014, 93, 603-608.	0.8	15
51	Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness. Mayo Clinic Proceedings, 2014, 89, 781-789.	1.4	31
52	Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). International Journal of Hematology, 2013, 97, 388-396.	0.7	6
53	Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. International Journal of Hematology, 2013, 97, 403-408.	0.7	19
54	Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia. Annals of Hematology, 2013, 92, 635-644.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Improved Electrical Characteristics of Honeycomb Nanowire ISFETs. <i>IEEE Electron Device Letters</i> , 2013, 34, 1059-1061.	2.2	23
56	Clinical features and treatment outcome of primary systemic light chain amyloidosis in Korea: Results of multicenter analysis. <i>American Journal of Hematology</i> , 2013, 88, 52-55.	2.0	14
57	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , 2013, 37, 1070-1076.	0.4	15
58	Investigation of the electrical stability of Si-nanowire biologically sensitive field-effect transistors with embedded Ag/AgCl pseudo reference electrode. <i>RSC Advances</i> , 2013, 3, 7963.	1.7	19
59	POEMS Syndrome Presenting with Acute Demyelinating Polyneuropathy: Increased Terminal Latency Indices and Uniform Demyelination. <i>Internal Medicine</i> , 2013, 52, 1513-1516.	0.3	1
60	Therapy-Related Myeloid Neoplasms in 39 Korean Patients: A Single Institution Experience. <i>Annals of Laboratory Medicine</i> , 2013, 33, 97-104.	1.2	9
61	Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2013, 28, 80.	1.1	4
62	Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. <i>Leukemia and Lymphoma</i> , 2012, 53, 173-175.	0.6	11
63	Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 118-126.	0.2	2
64	Impact of previous invasive pulmonary aspergillosis on the outcome of allogeneic hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2012, 47, 255.	0.7	4
65	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. <i>American Journal of Hematology</i> , 2012, 87, 37-41.	2.0	24
66	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. <i>Annals of Hematology</i> , 2012, 91, 249-256.	0.8	15
67	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	1.2	17
68	External Validation of Newly Proposed Cytogenetic Risk Classification in Patients Who Have Myelodysplastic Syndrome: A Retrospective Analysis at a Single Institution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 273-279.	0.2	0
69	pH sensing and noise characteristics of Si nanowire ion-sensitive field effect transistors. , 2011, , .		2
70	Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1630-1637.	2.0	32
71	Acquired Factor X Deficiency in Light Chain Amyloidosis: A Report of 2 Korean Cases. <i>Annals of Laboratory Medicine</i> , 2011, 31, 154-156.	1.2	2
72	Outcomes in critically ill patients with hematologic malignancies who received renal replacement therapy for acute kidney injury in an intensive care unit. <i>Journal of Critical Care</i> , 2011, 26, 107.e1-107.e6.	1.0	21

#	ARTICLE	IF	CITATIONS
73	Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 495-502.	1.4	13
74	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , 2011, 90, 1391-1398.	0.8	49
75	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	0.7	21
76	Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. <i>Leukemia and Lymphoma</i> , 2011, 52, 205-213.	0.6	18
77	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. <i>Haematologica</i> , 2011, 96, 1170-1179.	1.7	72
78	Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 353-357.	0.6	28
79	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. <i>Annals of Hematology</i> , 2010, 89, 201-206.	0.8	30
80	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). <i>Annals of Hematology</i> , 2010, 89, 489-497.	0.8	12
81	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. <i>Annals of Hematology</i> , 2010, 89, 905-912.	0.8	17
82	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. <i>Annals of Hematology</i> , 2010, 89, 1011-1018.	0.8	10
83	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	0.7	22
84	A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2010, 91, 886-891.	0.7	11
85	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	0.7	41
86	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 117-121.	1.0	13
87	Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. <i>European Journal of Haematology</i> , 2010, 84, 154-159.	1.1	51
88	BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 166-172.	0.4	31
89	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2010, 149, 537-549.	1.2	119
90	Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission. <i>The Korean Journal of Hematology</i> , 2010, 45, 95.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	0.7	15
92	Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. <i>Acta Haematologica</i> , 2010, 124, 92-97.	0.7	16
93	Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, e54-e55.	0.8	12
94	Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 2250-2257.	0.6	15
95	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1110-1118.	0.6	7
96	Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6027-6032.	0.8	312
97	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	0.7	28
98	Depletion of ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2009, 83, 108-118.	1.1	18
99	Clinical features and prognostic factors of patients with peripheral T cell lymphoma, unspecified. <i>Annals of Hematology</i> , 2009, 88, 111-119.	0.8	32
100	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. <i>Annals of Hematology</i> , 2009, 88, 639-645.	0.8	29
101	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , 2009, 88, 1099-1106.	0.8	21
102	Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 463-470.	2.0	55
103	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. <i>Leukemia and Lymphoma</i> , 2009, 50, 1119-1125.	0.6	21
104	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	0.6	63
105	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009, 113, 4309-4318.	0.6	75
106	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	1.2	7
107	Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 155-163.	1.4	18
108	ALK-positive diffuse large B-cell lymphoma: report of three cases. <i>Hematological Oncology</i> , 2008, 26, 108-113.	0.8	40

#	ARTICLE	IF	CITATIONS
109	Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. <i>European Journal of Haematology</i> , 2008, 81, 364-373.	1.1	44
110	Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 237-240.	1.4	59
111	Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1356-1364.	2.0	133
112	Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. <i>Leukemia and Lymphoma</i> , 2008, 49, 1929-1934.	0.6	26
113	Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis?. <i>Acta Haematologica</i> , 2008, 120, 199-206.	0.7	31
114	Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 88-94.	0.6	21
115	Outcomes of a Modified CALGB 19802 Regimen in Adult Acute Lymphoblastic Leukemia. <i>Journal of Korean Medical Science</i> , 2008, 23, 278.	1.1	1
116	Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. <i>Clinical Cancer Research</i> , 2007, 13, 3250-3254.	3.2	48
117	Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 716-722.	0.6	33
118	Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 463-468.	2.0	47
119	Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007, 258, 90-97.	3.2	19
120	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 972-978.	0.6	283
121	Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007, 48, 937-943.	0.6	6
122	A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy. <i>Journal of Korean Medical Science</i> , 2007, 22, 758.	1.1	16
123	Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. <i>American Journal of Hematology</i> , 2007, 82, 446-452.	2.0	41
124	Consideration of aggressive therapeutic strategies for primary testicular lymphoma. <i>American Journal of Hematology</i> , 2007, 82, 840-845.	2.0	39
125	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 359-364.	0.4	41
126	Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma. <i>Laboratory Investigation</i> , 2007, 87, 241-250.	1.7	21

#	ARTICLE	IF	CITATIONS
127	Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. <i>Clinical Immunology</i> , 2007, 125, 257-267.	1.4	64
128	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. <i>European Journal of Haematology</i> , 2007, 79, 287-291.	1.1	14
129	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. <i>Annals of Hematology</i> , 2007, 86, 493-498.	0.8	137
130	High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population. <i>Leukemia and Lymphoma</i> , 2006, 47, 2128-2131.	0.6	14
131	Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 612-618.	0.8	560
132	New Staging Systems Can Predict Prognosis of Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation as First-Line Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 837-844.	2.0	20
133	Pulmonary Complications After Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2006, 21, 406.	1.1	29
134	Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006, 30, 1253-1258.	0.4	10
135	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	0.7	32
136	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , 2006, 85, 285-290.	0.8	19
137	Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , 2006, 85, 781-786.	0.8	43
138	Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 91-96.	1.1	35
139	Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , 2006, 77, 304-308.	1.1	10
140	Isolated Blast Crisis in CNS in a Patient With Chronic Myelogenous Leukemia Maintaining Major Cytogenetic Response After Imatinib. <i>Journal of Clinical Oncology</i> , 2006, 24, 4028-4029.	0.8	23
141	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	0.6	18
142	An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1279-1285.	0.4	268
143	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263.	0.7	6
144	Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. <i>British Journal of Haematology</i> , 2005, 131, 59-66.	1.2	41

#	ARTICLE	IF	CITATIONS
145	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. Cellular Signalling, 2005, 17, 111-119.	1.7	24
146	Arsenic trioxide represses constitutive activation of NF- κ B and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of Cellular Biochemistry, 2005, 94, 695-707.	1.2	45
147	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-14.	1.1	40
148	Immunoreactivity of CD99 in Non-Hodgkin's Lymphoma: Unexpected Frequent Expression in ALK-positive Anaplastic Large Cell Lymphoma. Journal of Korean Medical Science, 2005, 20, 952.	1.1	21
149	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 214-217.	0.6	6
150	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biology of Blood and Marrow Transplantation, 2005, 11, 122-128.	2.0	35
151	Curcumin inhibits interferon- γ induced NF- κ B and COX-2 in human A549 non-small cell lung cancer cells. Biochemical and Biophysical Research Communications, 2005, 334, 313-318.	1.0	56
152	Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. European Journal of Cancer, 2005, 41, 1402-1408.	1.3	152
153	The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation. Journal of Korean Medical Science, 2004, 19, 79.	1.1	2
154	Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. Leukemia and Lymphoma, 2004, 45, 339-344.	0.6	50
155	Primary Pulmonary Non-Hodgkin's Lymphoma. Japanese Journal of Clinical Oncology, 2004, 34, 510-514.	0.6	103
156	Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4383-4388.	3.2	74
157	Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer. Oncology, 2004, 66, 32-37.	0.9	20
158	Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion, 2004, 44, 533-538.	0.8	8
159	A novel complex t(2;5;13)(p23;q35;q14) in small cell variant type anaplastic large cell lymphoma with peripheral involvement. Cancer Genetics and Cytogenetics, 2004, 154, 183-185.	1.0	11
160	Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea. International Journal of Hematology, 2004, 79, 185-188.	0.7	36
161	Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2004, 54, 385-390.	1.1	83
162	L-ascorbic acid represses constitutive activation of NF- κ B and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of Cellular Biochemistry, 2004, 93, 257-270.	1.2	41

#	ARTICLE	IF	CITATIONS
163	l-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 2180-2195.	1.2	82
164	Extrapulmonary Small-cell Carcinoma: a Single-institution Experience. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 250-254.	0.6	124
165	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480.	0.6	41
166	Esophageal Squamous Cell Carcinoma Recurring as a Solitary Renal Mass. <i>Cancer Research and Treatment</i> , 2004, 36, 271.	1.3	17
167	Three Cases of Synchronous Solid Tumor and Multiple Myeloma. <i>Cancer Research and Treatment</i> , 2004, 36, 338.	1.3	11
168	A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. <i>Lung Cancer</i> , 2003, 42, 227-235.	0.9	20
169	Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2003, 300, 230-235.	1.0	106
170	Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 533-537.	0.6	195
171	Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 509-513.	0.6	5
172	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 620-625.	0.6	3
173	Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 354-357.	0.6	18
174	Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2002, 71, 75-79.	2.0	63
175	Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 0, , 1-7.	1.4	0